Intimal Hyperplasia in Balloon Dilated Coronary Arteries is Reduced by Local Delivery of the NO Donor, SIN-1 Via a cGMP-Dependent Pathway

BMC Cardiovascular Disorders

Unne Stenram⁶  Anders Arner⁴  Eva Ekblad¹  Valéria Perez de Sá²  Evita Zoucas³  Jan Harnek⁵ 

[1] Department of Experimental Medical Science. Skane University Hospital. Institute of Clinical Sciences Lunds University, Getingev 4, SE-22185 Lund, Sweden;Department of Anaesthesiology. Skane University Hospital. Institute of Clinical Sciences. Lunds University, Getingev 4, SE-22185 Lund, Sweden;Department of Surgery. Skane University Hospital. Institute of Clinical Sciences. Lunds University. Getingev 4, SE-22185 Lund, Sweden;Department of Cellular Musclephysiology. Institute of Physiology and Pharmacology, Karolinska Institute, 171 77 Stockholm, Sweden;Department of Coronary Heart Disease. Skane University Hospital. Institute of Clinical Sciences. Lunds University, Getingev 4, SE-22185 Lund, Sweden;Department of Pathology. Skane University Hospital. Institute of Clinical Sciences. Lunds University. Getingev 4, SE-22185 Lund, Sweden

关键词: Remodeling;    Restenosis;    Endothelium-derived factors;    Angioplasty;    Nitric oxide;   

Others  :  1085971
DOI  :  10.1186/1471-2261-11-30

 received in 2010-10-29, accepted in 2011-06-11,  发布年份 2011

【 摘 要 】

Background

To elucidate the mechanism by which local delivery of 3-morpholino-sydnonimine (SIN-1) affects intimal hyperplasia after percutaneous transluminal coronary angioplasty (PTCA).

Methods

Porcine coronary arteries were treated with PTCA and immediately afterwards locally treated for 5 minutes, with a selective cytosolic guanylate cyclase inhibitor, 1 H-(1,2,4)oxadiazole(4,3-alpha)quinoxaline-1-one (ODQ) + SIN-1 or only SIN-1 using a drug delivery-balloon. Arteries were angiographically depicted, morphologically evaluated and analyzed after one and eight weeks for actin, myosin and intermediate filaments (IF) and nitric oxide synthase (NOS) contents.

Results

Luminal diameter after PCI in arteries treated with SIN-1 alone and corrected for age-growth was significantly larger as compared to ODQ + SIN-1 or to controls (p < 0.01). IF/actin ratio after one week in SIN-1 treated segments was not different compared to untreated segments, but was significantly reduced compared to ODQ + SIN-1 treated vessels (p < 0.05). Expression of endothelial NADPH diaphorase activity was significantly lower in untreated segments and in SIN-1 treated segments compared to controls and SIN-1 + ODQ treated arteries (p < 0.01). Restenosis index (p < 0.01) and intimal hyperplasia (p < 0.01) were significantly reduced while the residual lumen was increased (p < 0.01) in SIN-1 segments compared to controls and ODQ + SIN-1 treated vessels.

Conclusions

After PTCA local delivery of high concentrations of the NO donor SIN-1 for 5 minutes inhibited injury induced neointimal hyperplasia. This favorable effect was abolished by inhibition of guanylyl cyclase indicating mediation of a cyclic guanosine 3',5'-monophosphate (cGMP)-dependent pathway. The momentary events at the time of injury play crucial role in the ensuring development of intimal hyperplasia.

【 授权许可】

   
2011 Harnek et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Libby P: Inflammation in atherosclerosis. Nature 2002, 420(6917):868-874.
• [2]Pacher P, Beckman JS, Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007, 87:315-424.
• [3]Sarkar K, Sharma SK, Sachdeva R, Romeo F, Mehta JL: Coronary artery stenosis: vascular biology and emerging therapeutic strategies. Expert Rev Cardiovasc Ther 2006, 4(4):543-556.
• [4]Sarkar R, Gordon D, Stanley JC, Webb RC: Dual cell cycle-specific mechanism mediate the antimitogenic effects of nitric oxide in vascular smooth muscle cells. Hypertens 1997, 15:275-283.
• [5]Münzel T: Recent findings on nitrates: their action, bioactivation and development of tolerance. Dtsch Wochensch 2008, 133(44):2277-2282.
• [6]Kim YM, Bombeck CA, Billiar TR: Nitric oxide as a bifunctional regulator of apoptosis. Circ.Res 1999, 84:253-256.
• [7]Rabkin SW: Nitric oxide-induced cell death in the heart. The role of autophagy. Autophagy 2007, 3(4):347-349.
• [8]Maxell AJ: Mechanisms of dysfunction of the nitric oxide pathway in vascular disease. Nitric Oxide 2002, 6(2):101-124.
• [9]Shiraki T, Takamura A, Oka T, Saito D: Effect of short-term administration of high dose L-Arginine on restenosis after percutaneous coronary angioplasty. J Cardiol 2004, 44(1):13-20.
• [10]Yoon J, Wu C-j, Homme J, Tuch TJ, Wolff RG, Topol EJ, Lincoff AM: Local delivery of nitrix oxide from a eluting stent to inhibit neointimal thickening in a porcine coronary injury model. Yonsei Medical Journal 2002, 43(2):242-251.
• [11]Lablanche J-M, Grollier G, Lusson J-R, et al.: Effect of direct nitric oxide donors Linsidomine and Molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD study. Circulation 1997, 95(1):83-89.
• [12]Wohrle J, Hoher M, Nusser T, Kocks M: No effect of highly dosed nitric oxide donor molsidomine on the angiographic restenosis after percutaneous coronary angioplasty: a randomized, placebo controlled double-blind trial. Can J Cardiol 2003, 19(5):495-500.
• [13]Baek SH, Hrabie JA, Keefer LK, Hou D, Fineberg N, Rhoades R, March KL: Augmentation of intrapericardial nitric oxide level by a prolonged-release nitric oxide donor reduces luminal narrowing after porcine coronary angioplasty. Circulation 2002, 105:2779-2784.
• [14]Harnek J, Zoucas E, Sjuve R, Arner A, Ekblad E, Schou H, Perez de Sà V, Stenram U: Local infusion of the NO donor SIN-1 after angioplasty reduces intimal hyperplasia in porcine coronary arteries. Acta Radiol 2003, 44(4):395-402.
• [15]Palmer RMJ, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327:524-526.
• [16]Groves PH, Lewis MJ, Cheadle HA, Penny WJ: SIN-1 reduces platelet adhesion and platelet thrombus formation in a porcine model of balloon angioplasty. Circulation 1993, 87:590-597.
• [17]Furlong B, Henderson AM, Lewis MJ, Smith JA: Endothelium-derived relaxing factor inhibits in vitro platelet aggregation. Br. J. Pharmcol 1987, 90(4):687-692.
• [18]Malmqvist U, Arner A: Isoform distribution and tissue content of contractile and cytoskeletal proteins in hypertrophied smooth muscle from rat portal vein. Circ. Res 1990, 66(3):832-845.
• [19]Hope B, Michael GJ, Knigge KM, Vincent SR: Neuronal NADPH diaphorase is a nitric oxide synthase. Proc Natl Acad Sci USA 1991, 88:2811-2814.
• [20]Nugent HM, Rogers C, Edelman ER: Endothelial implants inhibit intimal hyperplasia after porcine angioplasty. Circ Res 1999, 84:384-391.
• [21]Bonan R, Paiement P, Scortichini D, Cloutier MJ, Leung TK: Coronary restenosis: Evaluation of a restenosis injury index in a swine model. Am Heart J 1993, 126(6):1334-1340.
• [22]Lee KW, Norell MS: Management of "no-reflow" complicating reperfusion therapy. Acute Card Care 2008, 10(1):5-14.
• [23]Pilz RB, Catsteel DE: Regulation of gene expression by cGMP. Circ Res 2003, 93:1034-1046.
• [24]Rudic RD, Shesely EG, Nobuyo M, Maeda N, Smithies O, Segal SS, Sessa WC: Direct evidence for the importance of endothelium derived Nitric Oxide in vascular remodeling. J.Clin.Invest 1998, 101(4):731-736.
• [25]Gratton JP, Bernatchez P, Sessa WC: Caveola and calveolins in the cardiovascular system. Circ.Res 2004, 94:1408-1417.
• [26]Shen YH, Wang XL, Wilken DE: Nitric oxide induces and inhibits apoptosis through different pathways. FEBS Lett 1998, 433(1-2):125-131.
• [27]Brüne B, von Knethen A, Sandau KB: Nitric oxide and its role in apoptosis. Eur.J.Pharmacol 1998, 351:261-272.
• [28]Beckman JS, Koppenol WH: Nitric oxide, superoxide and peroxynitrite: The good, the bad and the ugly. Am.J.Physiol 1996, 271:C1424-1437.
• [29]Radi R, Beckman JS, Bush KM, Freeman BA: Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J.Biol.Chem 1991, 266(7):4244-4250.
• [30]Kaji T, Kaieda I, Hisatsune T, Kaminogawa S: 3-Morpholinosydnonimine hydrochloride induces p53-dependent apoptosis in murine primary neural cells: A critical role for p21ras-MAPK-p19ARF pathway. Nitric Oxide 2002, 6(2):125-134.
• [31]Kocher O, Gabbiani G: Cytoskeletal features of normal and atheromatous human arterial smooth muscle cells. Hum Pathol 1986, 17(9):875-880.
• [32]Gabbiani G, Kocher O, Bloom WS, Vandekerckhove J, Weber K: Actin expression in smooth muscle cells of rat aortic intimal thickening, human atheromatous plaque, and cultured rat aortic media. J Clin Invest 1984, 73(1):148-152.
• [33]Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, Nagai R: Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002, 8(4):403-409.
• [34]Ursell PC, Mayes M: Anatomic distribution of nitric oxide synthetase in the heart. Int J Cardiol 1995, 50(3):217-223.
• [35]Persson K, Poljakovic M, Johansson K, Larsson B: Morphological and biochemical investigation of nitric oxide synthetase and related enzymes in the rat and pig urothelium. J Histochem Cytochem 1999, 47(6):739-750.
• [36]Shi Y, Niculescu R, Wang D, Patel S, Davenpeck KL, Zalewski A: Increased NAD(P)H oxidase and reactive species in coronary arteries after balloon injury. Arterioscler Tromb Vasc Biol 2001, 21:739-745.
• [37]Brüne B, Sandau K, Knethen A: Apoptotic cell death and nitric oxide: activating and antagonistic transducing pathways. Biochemistry (Mosc) 1998, 63(7):817-825.
• [38]Nobuyoshi M, Kimura T, Ohishi H, Horiuchi H, Nosaka H, Hamasaki N, Yokoi H, Kim K: Restenosis after percutaneous transluminal coronary angiography: pathologic observations in 20 patients. J Am Coll Cardiol 1991, 17(2):433-439.
• [39]Mintz GS, Popma JJ, Hong MK, Pichard AD, Kent KM, Satler LF, Leon MB: Intravascular ultrasound to discern device-specific effects and mechanisms of restenosis. Am J Cardiol 1996, 78(3A):18-22.